FdaApplication
NDA 022304
Identifiers
- fda_app_no: NDA022304
Properties
| Property | Value |
|---|---|
| applicant_name | COLLEGIUM PHARMACEUTICAL INC |
| application_type | NDA |
| approval_date | 2008-11-20 |
Revenue by product
NUCYNTA
| Period | Revenue |
|---|---|
| Q2 2026 | $19.5M |
| Q1 2026 | $28.8M |
| Q3 2025 | $32.0M |
| Q2 2025 | $53.0M |
| Q1 2025 | $54.8M |
| Q4 2024 | $24.2M |
| Q3 2024 | $25.4M |
| Q2 2024 | $25.2M |
| Q1 2024 | $26.0M |
| Q4 2023 | $27.2M |
| Q3 2023 | $24.9M |
| Q2 2023 | $28.2M |
| Q1 2023 | $27.9M |
| Q4 2022 | $28.9M |
| Q3 2022 | $27.3M |
Revenue as this company reported it for this product. A combination product's amount is stated once, for the product, and never divided across its ingredients. A fourth quarter is the reported full year less nine months, since no filing states one.
Products (3)
| Product | Active ingredient | Strength | Dosage form |
|---|---|---|---|
| NUCYNTA | TAPENTADOL HYDROCHLORIDE | EQ 50MG BASE | TABLET;ORAL |
| NUCYNTA | TAPENTADOL HYDROCHLORIDE | EQ 75MG BASE | TABLET;ORAL |
| NUCYNTA | TAPENTADOL HYDROCHLORIDE | EQ 100MG BASE | TABLET;ORAL |
3 products